

Andrea Sitlinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3463955/publications.pdf>

Version: 2024-02-01

25
papers

628
citations

933447

10
h-index

677142

22
g-index

27
all docs

27
docs citations

27
times ranked

856
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
2	Health-Related Quality of Life. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 675-684.	1.5	100
3	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
4	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
5	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
6	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
7	Impact of exercise on the immune system and outcomes in hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 1801-1811.	5.2	32
8	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
9	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
10	Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 317-321.	1.0	18
11	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
12	A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 23137.	3.3	9
13	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
14	A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22.	1.4	8
15	Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL). <i>Cells</i> , 2021, 10, 1165.	4.1	7
16	Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches. <i>Applied Clinical Informatics</i> , 2019, 10, 552-562.	1.7	6
17	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
18	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
20	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 3321-3321.	1.4	2
21	Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients. <i>Blood</i> , 2018, 132, 5540-5540.	1.4	1
22	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
23	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	1.4	0
24	Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina. <i>Blood</i> , 2019, 134, 3652-3652.	1.4	0
25	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 1-3.	1.4	0